MLKL 内皮のニッチでのPARylationは,がんの免疫監視と化学療法を回避するために血管新生死滅を引き起こす
Nan Yang1, Xiaoxue Li1, Wenwen Huang1
1Key Lab of Birth Defects and Related Diseases of Women and Children of MOE, State Key Lab of Biotherapy, State Key Laboratory of Respiratory Health and Multimorbidity, West China School of Basic Medical Sciences & Forensic Medicine, West China Second University Hospital, Sichuan University, Chengdu, China.
Nature cell biology
|September 5, 2025
まとめ
化学療法は卵巣がんや乳がんで 免疫抑制ニッチを作り出すことで 化学抵抗を誘発します これは,PARP1- SDF1軸を活性化させ,抗腫瘍免疫反応を阻害する内皮細胞を含む.
科学分野:
- 腫瘍学
- 免疫学
- 癌 生物学
背景:
- 化学抵抗はがん治療における大きな課題であり,治療の失敗と死亡率につながります.
- 腫瘍の微小環境は,治療への反応と抵抗を調節する上で重要な役割を果たします.
- 化学療法が腫瘍に関連した細胞の交響に影響を与えるメカニズムは,まだ完全に理解されていません.
研究 の 目的:
- 腫瘍の微小環境内の細胞相互作用を変えることで,化学療法が化学抵抗を誘発する方法を明らかにする.
- 化学療法による免疫抑制に関与する特定の分子経路と細胞タイプを特定する.
- 卵巣および乳がんにおける化学抵抗性における内皮細胞におけるPARP1-SDF1軸の役割を調査する.
主な方法:
- 卵巣がんと乳がんの臨床前マウスモデルとヒト患者のデータを統合
- 内皮細胞,マクロファージ,T細胞に焦点を当てた腫瘍の微小環境の分析.
- PARP1-SDF1信号軸とその調節に関する分子研究.
- 重要なタンパク質の相互作用と改変を特定するためのプロテオミックスクリーニング.
主要な成果:
- 化学療法により,ストロマル細胞由来因子1 (SDF1) が介在する免疫抑制性内皮ニッチの形成が促進される.
- 腫瘍内皮細胞 (ECs) のポリ (ADP-リボース) ポリメラーゼ1 (PARP1) -SDF1軸は,化学療法によって選択的に活性化されます.
- 化学療法によって誘発されるSDF1は,CXCL10+マクロファージとCXCR3+CD8+T細胞の相互作用を妨害することで,抗腫瘍免疫反応を阻害する.
- ENDOTHELIAL PARP1は,ネクロプトーシス効果因子であるPARylate MLKLを検出され,ECにおけるSDF1の産生を増加させた.
結論:
- 免疫抑制性腫瘍の微小環境を作り出すことによって 化学抵抗性を促進することができます
- 腫瘍内皮細胞におけるPARP1媒介性死滅は,SDF1を上昇調節し,免疫監視を回避する重要なメカニズムである.
- 内皮細胞におけるPARP1- SDF1軸をターゲットにすることは,化学抵抗を克服するための潜在的な治療戦略です.
関連する概念動画
The Intrinsic Apoptotic Pathway
6.8K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.8K
Regulation of Angiogenesis and Blood Supply
2.7K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K
Interactions Between Signaling Pathways
6.4K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K


